Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Neurocrine Biosciences, Inc. - Common Stock
(NQ:
NBIX
)
164.63
UNCHANGED
Delayed Quote
Updated: 4:00 PM EST, Nov 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Neurocrine Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Neurocrine (NBIX) Q3 2026 Earnings Call Transcript
↗
November 02, 2026
Record $1.1B revenue marks transformative quarter for diversified biotech.
Via
The Motley Fool
Topics
Earnings
Neurocrine Biosciences Q3 Earnings Call Highlights
↗
November 02, 2026
Neurocrine Biosciences (NASDAQ:NBIX) reported record third-quarter net product sales exceeding $1.1 billion and record operating profitability, supported by growth across its three marketed medicines:...
Via
MarketBeat
Topics
Earnings
Neurocrine Biosciences (NASDAQ:NBIX) Q3 Earnings Beat as INGREZZA Guidance Raised
↗
November 02, 2026
Via
Chartmill
Topics
Earnings
After-Hours Gainers and Losers: Nov. 2, 2026 Postmarket Review
↗
November 02, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX): A Debt-Free GARP Stock With Reasonable Growth
↗
November 02, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation
↗
October 28, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Stands Out as a Decent Value Stock
↗
October 05, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX): Affordable Growth at a Reasonable Valuation
↗
October 02, 2026
Via
Chartmill
Where Will Neurocrine Biosciences Be in 5 Years?
↗
October 25, 2026
Neurocrine's expanding drug portfolio could drive substantial growth through 2031.
Via
The Motley Fool
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
October 21, 2026
Growing investment in next-generation CNS cancer therapies is driving research into targeted drugs, immunotherapy and new approaches to treating aggressive brain tumors.
From
FN Media
Via
GlobeNewswire
Brain Cancer Research: The Race for Better CNS Cancer Treatments Could Open a Multibillion-Dollar Market
October 21, 2026
EQNX::TICKER_START (NASDAQ:NTHI),(NASDAQ:NBIX),(NASDAQ:ACAD),(NASDAQ:AVXL),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
Neurocrine Biosciences (NASDAQ:NBIX): An Affordable Growth Stock With Strong Momentum and Valuation
↗
August 29, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX): A Value Stock With Quality Behind the Discount
↗
August 05, 2026
Via
Chartmill
Neurocrine Maps AI, China and Pipeline Strategy as INGREZZA Faces 2029 Price Hit
↗
September 23, 2026
Neurocrine Biosciences (NASDAQ:NBIX) outlined its commercial growth priorities, pricing considerations and pipeline plans during a Morgan Stanley discussion, with CEO Kyle Gano emphasizing the...
Via
MarketBeat
Topics
Artificial Intelligence
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript
↗
August 03, 2026
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.
Via
The Motley Fool
Topics
Earnings
Neurocrine Biosciences Q2 Earnings Call Highlights
↗
July 31, 2026
Neurocrine Biosciences (NASDAQ:NBIX) reported second-quarter 2026 revenue of more than $950 million, nearly 40% higher than a year earlier, as sales of INGREZZA and CRENESSITY continued to grow and the...
Via
MarketBeat
Topics
Earnings
Neurocrine Biosciences (NASDAQ:NBIX): Strong Growth Stock with Technical Breakout Setup
↗
July 27, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High Growth Stock
↗
July 25, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Offers a High Growth Momentum Breakout Setup
↗
July 20, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Growth at a Reasonable Price Mold of Peter Lynch Screening
↗
July 16, 2026
Via
Chartmill
Neurocrine (NBIX) Q2 2026 Earnings Call Transcript
↗
July 30, 2026
Revenue hit $950 million as INGREZZA surged 15% and CRENESSITY grew 20%.
Via
The Motley Fool
Topics
Earnings
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen
↗
July 11, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shines in the "Little Book That Makes You Rich" Screen
↗
July 04, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Growth and Technical Breakout Setup
↗
July 01, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Fits the Profile of a Classic GARP Stock Under the Peter Lynch Framework
↗
June 24, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Decent Value Play with Strong Fundamentals
↗
June 20, 2026
Via
Chartmill
Neurocrine Biosciences (NASDAQ:NBIX) Screens as a High-Growth Momentum Breakout Candidate
↗
June 16, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Growth Stock Pick from the Little Book Strategy
↗
June 10, 2026
Via
Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Nears Technical Breakout with Near-Perfect Score
↗
June 08, 2026
Via
Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Peter Lynch GARP Opportunity with Strong Growth and a PEG Ratio of 0.82
↗
June 03, 2026
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
